## TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL

## **CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
Teva Pharmaceuticals USA, Inc.		05/13/2004	CORPORATION: DELAWARE

### **RECEIVING PARTY DATA**

Name:	Novopharm Limited
Street Address:	30 Novopharm Ct.
City:	Toronto
State/Country:	CANADA
Postal Code:	M1B 2K9
Entity Type:	CORPORATION: CANADA

PROPERTY NUMBERS Total: 2

Property Type	Number	Word Mark
Registration Number:	2721535	LOFIBRA
Serial Number:	78250359	LOFIBRA

## **CORRESPONDENCE DATA**

Fax Number: (212)732-3232

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-732-3200
Email: melnick@clm.com

Correspondent Name: Carter Ledyard & Milburn LLP

Address Line 1: 2 Wall St.

Address Line 4: New York, NEW YORK 10005

ATTORNEY DOCKET NUMBER: TEV01 005

#### DOMESTIC REPRESENTATIVE

Name:

Address Line 1: Address Line 2: Address Line 3:

TRADEMARK
REEL: 002851 FRAME: 0866

Address Line 4:	
NAME OF SUBMITTER:	Diane Melnick
Total Attachments: 1 source=Teva USA to Novopharm#page1.tif	

TRADEMARK
REEL: 002851 FRAME: 0867

# Trademark Assignment

WHEREAS, Teva Pharmaceuticals USA, Inc., a Delaware corporation, with its principal place of business at 1090 Horsham Road, North Wales, Pennsylvania 19454 USA ("Assignor"), has adopted, owns and is using the following trademarks (the "Marks") in connection with their respective goods, and holds a valid registration for the Mark as well as a pending application on the Principal Register of the United States Patent and Trademark Office with the registration number and application serial number noted below:

<u>Mark</u>	Registration No.	Goods
LOFIBRA	2,721,535	prescription drugs for lowering plasma triglycerides
Mark	Application Serial No.	Goods

WHEREAS, to the best of Assignor's knowledge no proceeding against said application is pending and no other party makes a claim of ownership to the Marks or the application therefor; and

WHEREAS, Novopharm Limited, a corporation of Canada, with its principal place of business at 30 Novopharm Court., Toronto, Ontario M1B 2K9 Canada ("Assignee"), desires to acquire the Marks and all associated goodwill in said Marks, and the pending application;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby sells, assigns and transfers to Assignee all right, title and interest in and to the Marks, together with the goodwill of the business symbolized by the Marks, and the pending application for

RECORDED: 05/17/2004 registration, and with all claims that could be asserted by Assignor arising on of the could be asserted by Assignor arising on of the could be asserted by Assignor arising on the